Navigation Links
DermaGen AB Receives Over 1 Million Euros From a New Share Issue
Date:4/2/2008

LUND, Sweden, April 2 /PRNewswire/ -- DermaGen AB today announced a cash injection from Midroc New Technology AB who now joins existing owners, Karolinska Development and Ostersjostiftelsen. The capital will be used for the further development of DermaGen's first candidate drug. The majority will be used to initiate a clinical phase 2a study in patients with Atopic Dermatitis (AD), for which the company has already received approval, and to further develop the company's R & D pipeline.

"We are pleased that the company has attracted a new investor. Both Karolinska Development and Ostersjostiftelsen continue to invest, reinforcing the financial strength of the company and enabling us to carry out a clinical trial with DPK-060. This is a novel antimicrobial treatment for AD, and our lead antimicrobial candidate for topical use, it will be tested in a phase 2a study in patients during 2008," says Jan Alenfall, CEO of DermaGen.

The move towards clinical activities marks a new phase for DermaGen and new members of the board of directors have been appointed to support this.

Jonas Frick, CEO Resistentia AB, was elected as Chairman of the Board of Directors at the annual meeting on the 31st of March. "DermaGen is a very exciting company and I am looking forward to contributing to the successful development of DermaGen's novel treatment options," says Jonas Frick.

Goran Linder, CEO of Midroc New Technology will also become member of DermaGen's Board of Directors. "As a pharmaceutical research company, DermaGen represents a new type of investment focus for Midroc New Technology, we see this as an extremely exciting new opportunity," says Goran Linder, CEO of Midroc New Technology.

Global sales of anti-infective drugs reached $44.5 billion in 2005 and will likely double over the next 5 years. Worldwide sales of products used in AD therapy are growing rapidly due to the increasing prevalence of the disease and are expected to reach $2 billion in 2013.

The disease is characterized by chronic and pruritic inflammation of the skin, which affects about 10-20 % of children and 1-3 % of adults worldwide Moderate-to-severe AD has a profound effect on the quality of life. Intractable itching, skin damage, soreness and sleep loss all compound the burden of disease. More than 90 % of all patients are colonized or infected by Staphylococcus aureus. These infections may aggravate the disease through the production of superantigens that induce an inflammation of the skin. In addition, these infections worsen the inflammation and increase the severity of the eczema. It is estimated that about 40 % of eczematous lesions are co-infected. Micro-organisms, therefore, are not merely aetiological factors, but may also be responsible for sustained disease activity as well as resistance to therapy. There is clearly an unmet medical need for topical antibiotics in this market.

About DermaGen

DermaGen AB founded in 2004, is a world leader in research on endogenous antimicrobial peptides. A specialty pharmaceutical company focusing on the development of topically applied products for the prevention and treatment of bacterial and fungal skin infections. Based on novel antimicrobial peptides, modified to increase potency and stability the products are designed to fulfil unmet medical need and significantly improve quality of life.

DermaGen partners with leading international pharmaceutical companies in the dermatological field.

Based in Lund, DermaGen functions as a virtual company, improving cost-effectiveness by engaging CROs and consultants when needed.

DermaGen is part of Karolinska Development Portfolio.

For more information, please visit http://www.dermagen.se.

About Midroc New Technology

Midroc New Technology AB is a Swedish venture capital company that invests at early stages in technologies with demonstrated prerequisites for a substantial, rapid and international break-through in the fields of Life Science, Security, and Clean Tech.

Midroc New Technology AB is part of Midroc Europe. The Group offers a wide range of management and contracting services to the civil and industrial market. In total the Group has 2 700 employees and an annual turnover amounting to SEK 4.0 billion.

About Karolinska Development

Karolinska Development commercializes Nordic life science innovation. Early stage investment enables value building through long term lead investor position, from seed stage to the market.

http://www.karolinskadevelopment.com

About the Ostersjostiftelsen

The Ostersjostiftelsen was established in 1994 by the Swedish government. In January 2007, the endowment's market value was approximately 7.1 billion Swedish kronor. There are two committees of the Board, one deals with finances and one for academic affairs. The Foundation is governed by a Board appointed by the Swedish government.

For further information please contact:

Jan Alenfall

CEO of DermaGen

ph: +46-46-286-4080

mobile: +46-709-315-115

e-mail: jan.alenfall@dermagen.se

Jonas Frick

Chairman of the Board

ph: +46-18-65-39-01

e-mail: info@dermagen.se

Goran Linder

CEO of Midroc New Technology AB

ph: +46-8-706-7450


'/>"/>
SOURCE DermaGen AB
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. PLC Systems Receives FDA Approval to Commence Pivotal Study Of RenalGuard(TM) In the U.S.
2. Diamyd(R) Diabetes Vaccine Receives Approval to Start Phase III Trials in Europe
3. Microbicide Developer Receives License for Novel HIV Microbicide Candidate From Merck & Co., Inc.
4. Florastor(R) Receives ConsumerLab.com Certification
5. DuraHeart(TM) LVAS Receives Conditional Approval for US Pivotal Trial
6. Vermillion Receives Award From the Society of Gynecologic Oncologists
7. Arbios Receives Conditional Approval from the FDA to Initiate Pivotal Clinical Trial for SEPET(TM)
8. ActivBiotics Receives Orphan Drug Designation from the European Medicines Agency for Superoxide Dismutase Mimetic, M40403, in Oral Mucositis Indication
9. Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency
10. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
11. Photo: Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... 17, 2017  Noble Capital Markets announced today that ... (Nasdaq: EPIX ). The report was issued ... , PhD. ESSA Pharmaceuticals is a clinical ... cancer (CRPC). Its lead compound EPI-506, is a small ... of the androgen receptor, thereby has potential to overcome ...
(Date:2/16/2017)... Quest Diagnostics (NYSE: DGX ), ... announced that it has been named one of the ... The annual survey designated Quest Diagnostics as ... Pharmacy and Other Services" industry to attain Most Admired ... attain the designation. This is the second consecutive year ...
(Date:2/16/2017)... Feb. 16, 2017  Aralez Pharmaceuticals Inc. (NASDAQ: ... company, today announced that executive management will participate in ... held February 22-23, 2017. Adrian Adams , Chief ... at 1:35 p.m. local time on Wednesday, February 22, ... for the event may be accessed from the Investors ...
Breaking Medicine Technology:
(Date:2/17/2017)... ... February 17, 2017 , ... For ... assistance management solution to the exhibit floor for the 2017 HIMSS Conference ... , From Feb. 19–23, 2017, more than 40,000 healthcare industry professionals are expected ...
(Date:2/17/2017)... Seattle, WA (PRWEB) , ... February 17, 2017 ... ... health management organizations, has been named a finalist in the 8th Annual DecisionHealth ... impacting America's healthcare delivery system. Qualis Health’s work is recognized across multiple award ...
(Date:2/17/2017)... ... 2017 , ... Pharmica Consulting attended CHI's 8th Annual SCOPE ... trial planning and management. Pharmica discussed the importance of effective project management, data ... by Pharmica’s booth were able to demo its cloud-based Resource Management Tool, ...
(Date:2/17/2017)... ... February 17, 2017 , ... Top neuroendocrine cancer doctors, nurses and specialists from ... February 21 - 23 in Beaver Creek, CO. It was announced today by Cindy ... year in Beaver Creek, hosting over 60 faculty members and addressing unmet needs of ...
(Date:2/16/2017)... ... 17, 2017 , ... For some cancer survivors, the memories ... Physician researchers at The Marcus Institute of Integrative Health at Thomas Jefferson ... reducing symptoms of traumatic stress in cancer patients and published their results ...
Breaking Medicine News(10 mins):